Crinetics Pharmaceuticals, Inc. (CRNX)
Automate Your Wheel Strategy on CRNX
With Tiblio's Option Bot, you can configure your own wheel strategy including CRNX - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol CRNX
- Rev/Share 0.0082
- Book/Share 13.4691
- PB 2.2644
- Debt/Equity 0.0405
- CurrentRatio 22.5272
- ROIC -0.2874
- MktCap 2857243050.0
- FreeCF/Share -2.8497
- PFCF -10.7692
- PE -8.6507
- Debt/Assets 0.0373
- DivYield 0
- ROE -0.3095
- Rating C
- Score 2
- Recommendation Sell
- P/E Score 1
- DCF Score 3
- P/B Score 2
- D/E Score 3
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Initiation | CRNX | Stifel | -- | Buy | -- | $60 | March 25, 2025 |
| Initiation | CRNX | TD Cowen | -- | Buy | -- | -- | Feb. 11, 2025 |
| Initiation | CRNX | Wolfe Research | -- | Peer Perform | -- | -- | Feb. 4, 2025 |
| Upgrade | CRNX | Jefferies | Hold | Buy | -- | $55 | Jan. 22, 2025 |
News
Crinetics Pharmaceuticals to Participate in the Jefferies Global Healthcare Conference 2025
Published: May 23, 2025 by: GlobeNewsWire
Sentiment: Neutral
SAN DIEGO, May 23, 2025 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX), today announced that company management will participate in the Jefferies Global Healthcare Conference, taking place June 3-5, 2025 in New York, NY.
Read More
Crinetics Pharma: Strong Progress With Multiple Indications And Upcoming PDUFA
Published: April 02, 2025 by: Seeking Alpha
Sentiment: Positive
Crinetics Pharma's lead asset, Paltusotine, shows promising Phase 3 results for acromegaly, with a PDUFA date set for September 25, 2024. Paltusotine, an oral SST2 agonist, offers advantages over injectable somatostatin analogs, achieving high IGF-1 control rates in pretreated patients. Positive Phase 2 data for Paltusotine in carcinoid syndrome and Atumelnant in congenital adrenal hyperplasia highlight CRNX's expanding therapeutic potential.
Read More
Crinetics Pharmaceuticals, Inc (CRNX) Q4 2024 Earnings Call Transcript
Published: February 28, 2025 by: Seeking Alpha
Sentiment: Neutral
Crinetics Pharmaceuticals, Inc (NASDAQ:CRNX ) Q4 2024 Results Conference Call February 27, 2025 4:30 PM ET Company Participants Gayathri Diwakar - Head-Investor Relations Scott Struthers - Founder and Chief Executive Officer Isabel Kalofonos - Chief Commercial Officer Dana Pizzuti - Chief Medical and Development Officer Steve Betz - Founder & Chief Scientific Officer Marc Wilson - Chief Financial Officer Alan Krasner - Chief Endocrinologist Conference Call Participants Tyler Van Buren - TD Cowen Joe Schwartz - Leerink Partners Jessica Fye - J.P. Morgan Gavin Clark-Gartner - Evercore ISI Catherine Okoukoni - Citizens Dennis Ding - Jefferies Catherine Novack - Jones …
Read More
Crinetics Pharmaceuticals Announces February 2025 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Published: February 10, 2025 by: GlobeNewsWire
Sentiment: Neutral
SAN DIEGO, Feb. 10, 2025 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX) today announced that on February 10, 2025, the Compensation Committee of the Board of Directors granted non-qualified stock option awards to purchase an aggregate of 105,100 shares of its common stock and granted an aggregate of 9,950 restricted stock unit (“RSU”) awards to 14 new non-executive employees, in each case, under the Crinetics Pharmaceuticals, Inc. 2021 Employment Inducement Incentive Award Plan (the “2021 Inducement Plan”). The stock options and RSUs were granted as inducements material to the employees entering into employment with Crinetics in accordance with Nasdaq …
Read More
About Crinetics Pharmaceuticals, Inc. (CRNX)
- IPO Date 2018-07-18
- Website https://www.crinetics.com
- Industry Biotechnology
- CEO Dr. R. Scott Struthers Ph.D.
- Employees 437